Epigenetics of osteoarticular diseases

recent developments

S. B. Roberts, E. Wootton, L. De Ferrari, Omar Al Bagha, D. M. Salter

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

A variety of osteoarticular conditions possess an underlying genetic aetiology. Large-scale genome-wide association studies have identified several genetic loci associated with osteoarticular conditions, but were unable to fully account for their estimated heritability. Epigenetic modifications including DNA methylation, histone modification, nucleosome positioning, and microRNA expression may help account for this incomplete heritability. This articles reviews insights from epigenetic studies in osteoarticular diseases, focusing on osteoarthritis, but also examines recent advances in rheumatoid arthritis, osteoporosis, systemic lupus erythematosus (SLE), ankylosing spondylitis, and sarcoma. Genome-wide methylation studies are permitting identification of novel candidate genes and molecular pathways, and the pathogenic mechanisms with altered methylation status are beginning to be elucidated. These findings are gradually translating into improved understanding of disease pathogenesis and clinical applications. Functional studies in osteoarthritis, rheumatoid arthritis, and SLE are now identifying downstream molecular alterations that may confer disease susceptibility. Epigenetic markers are being validated as prognostic and therapeutic disease biomarkers in sarcoma, and clinical trials of hypomethylating agents as treatments for sarcoma are being conducted. In concert with advances in throughput and cost-efficiency of available technologies, future epigenetic research will enable greater characterisation and treatment for both common and rare osteoarticular diseases.

Original languageEnglish
Pages (from-to)1293-1305
Number of pages13
JournalRheumatology International
Volume35
Issue number8
DOIs
Publication statusPublished - 20 Aug 2015
Externally publishedYes

Fingerprint

Epigenomics
Sarcoma
Osteoarthritis
Systemic Lupus Erythematosus
Methylation
Rheumatoid Arthritis
Histone Code
Genetic Loci
Nucleosomes
Genome-Wide Association Study
Ankylosing Spondylitis
Disease Susceptibility
Genetic Association Studies
DNA Methylation
Rare Diseases
MicroRNAs
Osteoporosis
Biomarkers
Clinical Trials
Genome

Keywords

  • Epigenetics
  • Methylation
  • Osteoarthritis
  • Osteoporosis
  • Rheumatoid arthritis
  • Sarcoma

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Epigenetics of osteoarticular diseases : recent developments. / Roberts, S. B.; Wootton, E.; De Ferrari, L.; Al Bagha, Omar; Salter, D. M.

In: Rheumatology International, Vol. 35, No. 8, 20.08.2015, p. 1293-1305.

Research output: Contribution to journalReview article

Roberts, SB, Wootton, E, De Ferrari, L, Al Bagha, O & Salter, DM 2015, 'Epigenetics of osteoarticular diseases: recent developments', Rheumatology International, vol. 35, no. 8, pp. 1293-1305. https://doi.org/10.1007/s00296-015-3260-y
Roberts, S. B. ; Wootton, E. ; De Ferrari, L. ; Al Bagha, Omar ; Salter, D. M. / Epigenetics of osteoarticular diseases : recent developments. In: Rheumatology International. 2015 ; Vol. 35, No. 8. pp. 1293-1305.
@article{a32a3b91e46f4924822e65a3e32705d0,
title = "Epigenetics of osteoarticular diseases: recent developments",
abstract = "A variety of osteoarticular conditions possess an underlying genetic aetiology. Large-scale genome-wide association studies have identified several genetic loci associated with osteoarticular conditions, but were unable to fully account for their estimated heritability. Epigenetic modifications including DNA methylation, histone modification, nucleosome positioning, and microRNA expression may help account for this incomplete heritability. This articles reviews insights from epigenetic studies in osteoarticular diseases, focusing on osteoarthritis, but also examines recent advances in rheumatoid arthritis, osteoporosis, systemic lupus erythematosus (SLE), ankylosing spondylitis, and sarcoma. Genome-wide methylation studies are permitting identification of novel candidate genes and molecular pathways, and the pathogenic mechanisms with altered methylation status are beginning to be elucidated. These findings are gradually translating into improved understanding of disease pathogenesis and clinical applications. Functional studies in osteoarthritis, rheumatoid arthritis, and SLE are now identifying downstream molecular alterations that may confer disease susceptibility. Epigenetic markers are being validated as prognostic and therapeutic disease biomarkers in sarcoma, and clinical trials of hypomethylating agents as treatments for sarcoma are being conducted. In concert with advances in throughput and cost-efficiency of available technologies, future epigenetic research will enable greater characterisation and treatment for both common and rare osteoarticular diseases.",
keywords = "Epigenetics, Methylation, Osteoarthritis, Osteoporosis, Rheumatoid arthritis, Sarcoma",
author = "Roberts, {S. B.} and E. Wootton and {De Ferrari}, L. and {Al Bagha}, Omar and Salter, {D. M.}",
year = "2015",
month = "8",
day = "20",
doi = "10.1007/s00296-015-3260-y",
language = "English",
volume = "35",
pages = "1293--1305",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Epigenetics of osteoarticular diseases

T2 - recent developments

AU - Roberts, S. B.

AU - Wootton, E.

AU - De Ferrari, L.

AU - Al Bagha, Omar

AU - Salter, D. M.

PY - 2015/8/20

Y1 - 2015/8/20

N2 - A variety of osteoarticular conditions possess an underlying genetic aetiology. Large-scale genome-wide association studies have identified several genetic loci associated with osteoarticular conditions, but were unable to fully account for their estimated heritability. Epigenetic modifications including DNA methylation, histone modification, nucleosome positioning, and microRNA expression may help account for this incomplete heritability. This articles reviews insights from epigenetic studies in osteoarticular diseases, focusing on osteoarthritis, but also examines recent advances in rheumatoid arthritis, osteoporosis, systemic lupus erythematosus (SLE), ankylosing spondylitis, and sarcoma. Genome-wide methylation studies are permitting identification of novel candidate genes and molecular pathways, and the pathogenic mechanisms with altered methylation status are beginning to be elucidated. These findings are gradually translating into improved understanding of disease pathogenesis and clinical applications. Functional studies in osteoarthritis, rheumatoid arthritis, and SLE are now identifying downstream molecular alterations that may confer disease susceptibility. Epigenetic markers are being validated as prognostic and therapeutic disease biomarkers in sarcoma, and clinical trials of hypomethylating agents as treatments for sarcoma are being conducted. In concert with advances in throughput and cost-efficiency of available technologies, future epigenetic research will enable greater characterisation and treatment for both common and rare osteoarticular diseases.

AB - A variety of osteoarticular conditions possess an underlying genetic aetiology. Large-scale genome-wide association studies have identified several genetic loci associated with osteoarticular conditions, but were unable to fully account for their estimated heritability. Epigenetic modifications including DNA methylation, histone modification, nucleosome positioning, and microRNA expression may help account for this incomplete heritability. This articles reviews insights from epigenetic studies in osteoarticular diseases, focusing on osteoarthritis, but also examines recent advances in rheumatoid arthritis, osteoporosis, systemic lupus erythematosus (SLE), ankylosing spondylitis, and sarcoma. Genome-wide methylation studies are permitting identification of novel candidate genes and molecular pathways, and the pathogenic mechanisms with altered methylation status are beginning to be elucidated. These findings are gradually translating into improved understanding of disease pathogenesis and clinical applications. Functional studies in osteoarthritis, rheumatoid arthritis, and SLE are now identifying downstream molecular alterations that may confer disease susceptibility. Epigenetic markers are being validated as prognostic and therapeutic disease biomarkers in sarcoma, and clinical trials of hypomethylating agents as treatments for sarcoma are being conducted. In concert with advances in throughput and cost-efficiency of available technologies, future epigenetic research will enable greater characterisation and treatment for both common and rare osteoarticular diseases.

KW - Epigenetics

KW - Methylation

KW - Osteoarthritis

KW - Osteoporosis

KW - Rheumatoid arthritis

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84931567319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931567319&partnerID=8YFLogxK

U2 - 10.1007/s00296-015-3260-y

DO - 10.1007/s00296-015-3260-y

M3 - Review article

VL - 35

SP - 1293

EP - 1305

JO - Rheumatology International

JF - Rheumatology International

SN - 0172-8172

IS - 8

ER -